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Introduction {#sec001}
============

The proto-oncogene c-Jun, one of the most studied transactivator proteins, is a major component of the heterodimeric AP-1 transcription factor family \[[@pone.0232635.ref001]\]. Activated c-Jun is transported into the nucleus, where it forms the AP-1 heterodimer complex and binds to promoter regions of target genes. Phosphorylation of c-Jun at Serine 63 (Ser63) and Ser73 by c-Jun N-terminal kinase (JNK) regulates c-Jun transcription activities \[[@pone.0232635.ref002], [@pone.0232635.ref003]\]. The c-Jun/JNK pathway is activated by various extracellular stimuli, including infection, inflammation, oxidative stress, DNA damage, osmotic stress, and cytoskeletal changes \[[@pone.0232635.ref004]\]. As JNK is a key component of the innate immunity pathways, pathogens have developed strategies to modulate the JNK signaling events \[[@pone.0232635.ref004]\]. While suppression of JNK signaling has some advantages to many pathogens, other pathogens activate the JNK pathway. For example, Epstein-Barr virus (EBV) LMP1 activates JNK through TRAF signaling \[[@pone.0232635.ref005]\]. Human cytomegalovirus (HCMV) IE1 activates the phosphorylation of c-Jun \[[@pone.0232635.ref006]\]. Further, the activation of JNK is essential for effective viral protein expression and replication in varicella-zoster virus-infected neuronal cells \[[@pone.0232635.ref007]\]. Therefore, the regulation of c-Jun/JNK signaling by viral proteins is important for the replication of some viruses.

The UL42 gene product of HCMV is a membrane protein that contains two PPXY (PY) motifs to interact with Itch, a member of the ubiquitin E3 ligase Nedd4 family \[[@pone.0232635.ref008]\]. UL42 and its alpha- and beta-herpesvirus homologs share a number of conserved structures including the PY motifs in their N-terminal domain and the C-terminal transmembrane domain (TMD), but the function of other domains remains to be elucidated \[[@pone.0232635.ref009]--[@pone.0232635.ref011]\]. All these homologs interact with Itch through their PY motifs. As Itch ubiquitinates various substrates, it plays multiple roles in signal transduction, intracellular trafficking, cell survival and immune responses \[[@pone.0232635.ref012]\]. Indeed, Itch is involved in the negative regulation of c-Jun/JNK signaling through ubiqutination of c-Jun \[[@pone.0232635.ref013]\]. Fu and colleagues have recently reported that UL42 inhibits DNA binding, oligomerization and enzymatic activity of cyclic GMP-AMP synthase to antagonize innate antiviral responses in a Nedd4 family- independent manner \[[@pone.0232635.ref014]\].

In the present study, we investigated whether UL42 regulated c-Jun activation through its interaction with Itch. For this purpose, we performed mapping of the UL42 functional domains for AP-1 transcriptional activation, nuclear localization of c-Jun, and phosphorylation of c-Jun and JNK. Unexpectedly, we found that UL42 activated c-Jun in an Itch-independent manner. Thus, UL42 has the ability to regulate JNK signaling among HCMV-encoded proteins.

Materials and methods {#sec002}
=====================

Cells {#sec003}
-----

The HEK293T cells (RIKEN Cell Bank, Tsukuba, Japan) were cultured in Dulbecco's minimum essential medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100U/ml penicillin and 100U/ml streptomycin. Immortalized human fibroblasts (hTERT-BJ1) were cultured in DMEM-medium 199 (4:1) supplemented with 10% FBS, 2 mM L-glutamine, 1 mM sodium pyruvate, 100 U/ml penicillin, and 100 μg/ml streptomycin.

Plasmids and transfection {#sec004}
-------------------------

pCAGGS-HAUL42WT, pCAGGS expressing wild-type UL42 with an HA-tag at the N-terminus, was described previously \[[@pone.0232635.ref008], [@pone.0232635.ref015]\]. Primers P1-13 used in this report were shown in Supporting Information ([S1 Table](#pone.0232635.s002){ref-type="supplementary-material"}). pCAGGS-HAUL42ΔN and -HAUL42ΔI, pCAGGS expressing HA-tagged UL42 lacking the amino acid (a.a.) 1--50 and 51--86 regions, respectively ([Fig 1A](#pone.0232635.g001){ref-type="fig"}), were constructed by the inverse PCR-based method using pCAGGS-HAUL42WT as a template along with primer pairs P1 and P2 for ΔN and P3 and P4 for ΔI, respectively.

![UL42 mutant constructs and their ability to activate AP-1-dependent transcription.\
A. HCMV UL42 has two PY motifs (closed boxes) and a C-terminal transmembrane domain (TMD; a closed box in gray). In the PA and AY mutants, the PPXY sequences were substituted to PPXA (open boxes) and AAXY (hatched boxes), respectively. UL42 and its mutated forms were fused with HA or EGFP tags at the N-terminus of UL42. Residue numbers are based on the position in wild-type (WT) UL42. B and C. Indicated plasmid expressing HA-tagged (B) or EGFP-tagged (C) UL42 mutants and the luciferase reporter and control plasmids, pAP1(PMA)-TA-Luc and pRL-TK, were transfected into HEK293T cells. Means ± SEMs of the ratios of firefly luciferase activities to Renilla luciferase activities obtained in three independent experiments ([S1 Fig](#pone.0232635.s003){ref-type="supplementary-material"}) are shown. The p-values were determined by the one-way ANOVA followed by the Tukey\'s multiple comparison test. \*\*p\<0.01, \*\*\*p\<0.005, \*\*\*\*p\<0.001. (B) pCAGGS (Vec), pCAGGS-HAUL42WT (WT), -HAUL42PA (PA), -HAUL42ΔN (ΔN), and -HAUL42ΔI (ΔI). (C) pEGFP-C1 (Vec), -UL42WT (WT), -UL42AY (AY), and -UL42Ct (Ct).](pone.0232635.g001){#pone.0232635.g001}

A PCR-amplified fragment encoding the UL42 open reading frame using with primers P5 and P6 was inserted between the BamHI and XhoI sites of pEGFP-C1 (Takara Bio, Shiga, Japan) to construct pEGFP-UL42WT. pEGFP-UL42AY, a PY motif-disrupted (PPXY to AAXY alteration) mutant, was constructed by the QuickChange site-directed mutagenesis (Agilent technologies, St Clara, CA) of pEGFP-UL42WT using primers P8-P11.

The C-terminal TMD of UL42 was amplified by PCR using primers P4 and P7 and inserted between the BglII and SalI sites of pEGFP-C1, generating pEGFP-UL42Ct. Integrities of all inserts were confirmed by DNA sequencing. All plasmids used were purified with a Qiagen plasmid plus midi kit (Qiagen, Venlo, Netherlands). HEK293T cells were transfected with the indicated plasmids using ScreenFect A (Fuji-Film Wako Pure Chemical, Osaka, Japan).

Luciferase assay {#sec005}
----------------

The control and reporter plasmids, 0.01 μg/well of pRL-TK (Promega, Madison, WI) and 0.1μg/well of pAP1(PMA)-TA-Luc, which contains the firefly luciferase gene under the control of a minimal promoter with multiple copies of the AP-1 enhancer elements (Takara Bio), and 0.1 μg/well of UL42 expression plasmids were transfected to HEK293T cells in 96-well plates. At 48h post-transfection, the luciferase activity of the cells was analyzed with a Dual-Glo Luciferase assay kit (Promega). The ratios of firefly luciferase activities to Renilla luciferase activities were obtained in triplicated wells in each experiment.

Antibodies {#sec006}
----------

The anti-HA rabbit polyclonal antibody, and anti-GFP monoclonal antibody (dilution ratio 1:1000) (MBL, Nagoya, Japan), anti-c-Jun (dilution ratio 1:1000), anti-phospho-c-Jun (S63) (dilution ratio 1:1000), and anti-Itch monoclonal antibodies (dilution ratio 1:1000) (BD Bioscience, Franklin Lakes, NJ), anti-JNK and phospho-JNK rabbit polyclonal antibodies (dilution ratio 1:250)(Cell Signaling Technology, Danvers, MA), and anti-actin monoclonal antibody (dilution ratio 1:5000) (Merck, Darmstadt, Germany) were purchased as indicated. Anti-UL42 rabbit polyclonal antibody was raised against GST-UL42 (dilution ratio 1:2000). Peroxidase-conjugated anti-mouse or anti-rabbit IgG antibodies (dilution ratio 1:2000 and 1:5000, respectively) (GE healthcare, Chicago, IL), and Alexa Fluor 488-, 594- or 647-conjugated antibodies (Thermo Fisher Scientific, Waltham, MA) were used as the secondary antibodies.

Immunoblots and immunofluorescence analysis {#sec007}
-------------------------------------------

Immunoblotting analyses were performed essentially as described elsewhere \[[@pone.0232635.ref009]\]. In brief, HEK293T cells were transfected with 0.6 μg/well of plasmids, cultured for 48h and lysed in the Laemmli's sample buffer. After boiling at 98 °C for 5 min and brief sonication, cell lysates were separated on sodium dodecyl sulfate-poly-acrylamide gels and transferred to PVDF membranes (Millipore). After blocking with PBS-T (0.05% Tween 20 in PBS) containing 5% skim milk (Fuji-Film Wako Pure Chemical), the membranes were washed three times with PBS-T and incubated with primary antibodies diluted in PBS-T containing 1% bovine serum albumin (BSA) at 4 °C for overnight. After washing three times with PBS-T, membranes were incubated with peroxidase-conjugated secondary antibodies diluted into PBS-T containing 5% skim-milk at room temperature for 3 h, and then washed three times with PBS-T. After reaction with Immunostar LD reagent (Fuji-Film Wako Pure Chemical), signals were detected in ChemiDoc system (BioRad Laboratories, Hercules, CA).

Cells were grown on coverslips and fixed with 4% paraformaldehyde in PBS at 48 h post-transfection. The cells were permeabilized with PBS containing 0.05% Triton X-100 and stained with DAPI (Thermo Fisher Scientific) and the indicated antibodies at room temperature for 30 min. Samples were mounted on slide glass with antifade (Thermo Fisher Scientific) and analyzed with confocal microscopy (LSM700, Carl Zeiss, Oberkochen, Germany). Data capture was done under conditions identical among series of the samples.

Recombinant HCMV strains {#sec008}
------------------------

The recombinant viruses were constructed using the two-step Red-mediated mutagenesis \[[@pone.0232635.ref016]\]. To recover the epithelial and endothelial cell tropisms of HCMV strain Towne, the UL130 gene was repaired as described previously \[[@pone.0232635.ref017]\] to generate TowBACdTT-WT genome. The UL42 open reading frame was deleted from TowBACdTT-WT genome to construct TowBACdTT-ΔUL42 as described previously \[[@pone.0232635.ref008]\]. Briefly, a DNA fragment containing kanamycin resistant gene (Km^r^) and I-SceI site was amplified with primers P12 and P13 and inserted into pCAGGS-UL42WT and pCAGGS-UL42PA. I-SceI-Km^r^-UL42 fragments were amplified with primers P13 and P14, inserted into TowBACdTT-ΔUL42 genome, and Km^r^ sequence was removed to generate TowBACdTT-UL42R and TowBACdTT-UL42PA. Successful recombination was confirmed by PCR, Southern blotting and DNA sequencing. Those BAC genomes were purified using a Nucleobond BAC 100 kit (TaKaRa Bio) and transfected to human fibroblasts to reconstitute infectious recombinant viruses.

Statistical analysis {#sec009}
--------------------

Data of luciferase assays and cell counting were based on three independent experiments, and each set of experimental results was analyzed statistically with GraphPad PRISM software ver.8.3 (GraphPad Software, San Diego, CA). The luciferase data obtained in triplicated wells were analyzed with the one-way ANOVA test followed by the Tukey\'s multiple comparison test. Immunofluorescence assay data were digitalized with Photoshop software (Adobe systems, San Jose, CA), and the percentages of nuclear c-Jun-positive cells among the cells expressing UL42 derivatives or EGFP were obtained in three random fields in each experiment. Then, the percentages obtained in three independent experiments were analyzed with the one-way ANOVA test followed by the Tukey\'s multiple comparison test.

Results {#sec010}
=======

AP-1 signaling activation by UL42 expression {#sec011}
--------------------------------------------

To measure the AP-1-dependent transcriptional activities, HEK293T cells were transfected with a UL42-expressing plasmid and a reporter plasmid, pAP1(PMA)-TA-Luc, for a luciferase assay. Expression of UL42 wild type (WT) enhanced luciferase activities ([Fig 1B](#pone.0232635.g001){ref-type="fig"}). Expression of UL42 mutant protein UL42PA, which contains alterations of the two PPXY (PY) motifs to the PPXA (PA) motifs to abolish binding activity to the Nedd4 family, yielded the same luciferase activity as UL42WT. We constructed several deletion mutants of UL42 ([Fig 1A](#pone.0232635.g001){ref-type="fig"}) to identify the domain responsible for AP-1 transcriptional activation. The deletion of the N-terminal region (ΔN) induced luciferase activity as that of UL42WT, but the deletion of the internal region (ΔI) showed reduced activity, suggesting the requirement of the C-terminal TMD for the AP-1 signaling. To confirm two observations described above, *i*.*e*. no involvement of the Nedd4 family E3 ligases and the requirement of the C-terminal TMD for induction of the AP-1 signaling, we constructed EGFP-UL42AY and EGFP-UL42Ct for the respective purposes. EGFP-tagged UL42 derivatives EGFP-UL42WT and -UL42AY but not EGFP-UL42Ct which contains only C-terminal TMD activated AP-1 signaling ([Fig 1C](#pone.0232635.g001){ref-type="fig"}), indicating that the C-terminal half of UL42 rather than the PY motifs is essential for the activation of AP-1-dependent transcription.

The nuclear accumulation of c-Jun by UL42 expression {#sec012}
----------------------------------------------------

As it is well known that the activated form of c-Jun is translocated to the nucleus for AP-1 formation, we examined the intracellular localization of c-Jun in UL42-expressing cells. As shown in [Fig 2](#pone.0232635.g002){ref-type="fig"}, transfection with a plasmid expressing UL42WT, PA orΔN increased the numbers of c-Jun-positive nuclei in comparison with transfection with a control vector plasmid. C-Jun was only weakly detectable in cells expressing UL42ΔI. As reported previously, UL42WT and UL42PA were localized in cytoplasmic membranous structures \[[@pone.0232635.ref008]\]. The mutant proteins containing the C-terminal TMD were localized in the cytoplasmic structures and such localizing patterns resembled that of UL42WT. In addition, the percentages of nuclear c-Jun-positive cells in cells expressing HA-tagged UL42 derivatives were evaluated as described in Materials and Methods. C-Jun was highly accumulated in the nuclei of cells expressing HA-tagged UL42WT, UL42PA and UL42ΔN but not those expressing HA-tagged UL42ΔI ([Fig 2A](#pone.0232635.g002){ref-type="fig"}), and the defect of UL42ΔI was statistically significant ([Fig 2B](#pone.0232635.g002){ref-type="fig"}).

![Intracellular localization of HA-tagged UL42 mutants and c-Jun.\
A. Detection of c-Jun and HA-tagged UL42 derivatives. The HEK293T cells were transfected with pCAGGS, pCAGGS-HAUL42WT (WT), -HAUL42PA (PA), -HAUL42ΔN (ΔN), or -HAUL42ΔI (ΔI), and reacted with anti-c-Jun and anti-HA antibodies, and then with Alexa Fluor 488- and 594-conjugated secondary antibodies for c-Jun (shown in green) and UL42 (in red). The nuclei of the cells were stained with DAPI (blue). B. The percentages of nuclear c-Jun-positive cells among UL42 or its derivative expressing cells. Mean ± SEM of the percentages obtained in three independent experiments are shown. Statistical differences were determined by the one-way ANOVA followed by the Tukey\'s multiple comparison test. \*\*p\<0.01, \*\*\*p\<0.005.](pone.0232635.g002){#pone.0232635.g002}

To confirm the results based on HA-tagged UL42 derivatives, we evaluated the nuclear accumulation of c-Jun using EGFP-tagged UL42 derivatives ([Fig 3A and 3B](#pone.0232635.g003){ref-type="fig"}). EGFP-UL42WT was localized in the cytoplasmic membranous structures as HA-tagged UL42WT ([S2A and S2B Fig](#pone.0232635.s004){ref-type="supplementary-material"}). Although the subcellular localization of EGFP-UL42AY was similar to that of EGFP-UL42WT, EGFP-UL42Ct was detected in a mesh-like localization pattern in the cytoplasm ([S2B Fig](#pone.0232635.s004){ref-type="supplementary-material"}), which is the characteristic of ER localization. As shown in [Fig 3A and 3B](#pone.0232635.g003){ref-type="fig"}, the expression of EGFP-UL42WT and -UL42AY but not of EGFP-UL42Ct induced the nuclear localization of c-Jun in HEK293T cells. The percentages of nuclear c-Jun-positive cells were increased by expression of EGFP-UL42WT and -UL42AY but not of EGFP-UL42Ct ([Fig 3B](#pone.0232635.g003){ref-type="fig"}). These results indicate that the C-terminal TMD alone was not sufficient for the nuclear accumulation of c-Jun.

![Intracellular localization of EGFP-tagged UL42 mutants and c-Jun.\
A. The plasmids expressing the indicated proteins were transfected to HEK293T cells. The cells were reacted with anti-c-Jun and then with Alexa Fluor 647-conjugated secondary antibody (shown in red). EGFP fluorescence and nuclei staining with DAPI are shown in green and blue, respectively. B. The percentages of nuclear c-Jun-positive cells among cells expressing EGFP (Vec), EGFP-UL42WT (WT), -UL42AY (AY), or -UL42Ct (Ct). Mean ± SEM and statistical differences are shown as described in the legend for [Fig 2B](#pone.0232635.g002){ref-type="fig"}. \*p\<0.05, \*\*p\<0.01.](pone.0232635.g003){#pone.0232635.g003}

JNK and c-Jun phosphorylation by UL42 expression {#sec013}
------------------------------------------------

The phosphorylation status of c-Jun, JNK and Itch were analyzed by immunoblotting using lysates of cells expressing UL42 or its mutated forms ([Fig 4](#pone.0232635.g004){ref-type="fig"}). As shown in [Fig 4A](#pone.0232635.g004){ref-type="fig"}, UL42ΔN could be more sensitive to proteolytic cleavage, as 17 kDa and 8 kDa bands were detected in addition to the 24 kDa full-length product. As reported previously \[[@pone.0232635.ref008]\], the amount of Itch was decreased by the expression of UL42WT but not of UL42PA. The Ser63 residue of c-Jun was phosphorylated by the expression of UL42WT and UL42PA ([Fig 4A](#pone.0232635.g004){ref-type="fig"}). The phosphorylation was further increased by UL42ΔN expression. In addition, JNK was highly phosphorylated by UL42WT, PA and ΔN. In contrast, ΔI only weakly induced the phosphorylation of c-Jun and JNK, while ΔI, which possesses the PPXY motifs, significantly decreased Itch amount. C-Jun and JNK were phosphorylated by the expression of EGFP-UL42WT and -UL42AY but not by EGFP-UL42Ct.

![Detection of phosphorylated JNK, c-Jun and Itch in cells expressing UL42 derivatives.\
A. Lysates of HEK293T cells transfected with pCAGGS (Vec), pCAGGS-HAUL42WT (WT), -HAUL42PA (PA), -HAUL42ΔN (ΔN), or -HAUL42ΔI (ΔI) were analyzed by immunoblotting using antibodies for the detection of the indicated forms of proteins. Ratios of band intensities between the forms of the indicated protein without and with phosphorylation were analyzed with NIH imageJ software, and indicated beneath the panels. B. Lysates of HEK293T cells transfected with pEGFP-C1 (Vec), pEGFP-UL42WT (WT), -UL42AY (AY), or -UL42Ct (Ct) were analyzed by immunoblotting using antibodies for the detection of the indicated forms of proteins.](pone.0232635.g004){#pone.0232635.g004}

In spite of the evident effect of UL42 on c-Jun in transfection assays, the phosphorylation status of c-Jun was not affected by UL42 expression in HCMV-infected cells ([S3 Fig](#pone.0232635.s005){ref-type="supplementary-material"}).

Discussion {#sec014}
==========

Our results revealed that HCMV UL42 induced AP-1 signaling by the activation of the c-Jun/JNK pathway. UL42 expression increased the phosphorylation of JNK as well as that of c-Jun Ser63, one of two JNK-mediated phosphorylation sites required for the promotion of c-Jun transactivation activity \[[@pone.0232635.ref001]\]. UL42 reduced Itch amount, a member of the ubiquitin E3 ligase Nedd4 family \[[@pone.0232635.ref008]\]. Itch belongs to the negative feedback mechanism of JNK, as activated Itch ubiquitinates c-Jun to induce their degradation \[[@pone.0232635.ref012], [@pone.0232635.ref013]\]. Importantly, however, the lack of the PY motif for binding to Itch in UL42PA and ΔN mutants did not decrease JNK signaling, indicating that Itch is not involved in the UL42-mediated JNK activation. Although the phosphorylation levels of c-Jun seems weak in EGFP-UL42WT and -AY expressing cells as compared to those in cells expressing HA-tagged UL42WT and PA, the phosphorylation of JNK was significantly increased in EGFP-UP42WT and -AY expressing cells ([Fig 3B](#pone.0232635.g003){ref-type="fig"}). We assume that steric hindrance due to EGFP fusion reduced the levels partially. In fact, the results of luciferase assay ([Fig 1C](#pone.0232635.g001){ref-type="fig"}) and nuclear translocation of c-Jun ([Fig 3](#pone.0232635.g003){ref-type="fig"}) supported the notion that the phosphorylation of c-Jun and activation of AP-1 signaling occurred by expression of EGFP-UL42WT and -AY but not -Ct. As JNK is a member of MAPK, which is activated by various stimuli, including infection, inflammation, oxidative stress, DNA damage, stimulation, if at all, of these signaling pathways.

The results of our domain mapping experiments suggest that the a.a. 52--86 region of UL42 is responsible for the c-Jun nuclear localization, as the a.a. 52--124 region, but not the C-terminal TMD itself, activated AP-1 signaling ([Fig 1](#pone.0232635.g001){ref-type="fig"}), re-localized c-Jun to the nucleus (Figs [2](#pone.0232635.g002){ref-type="fig"} and [3](#pone.0232635.g003){ref-type="fig"}), and c-Jun phosphorylation ([Fig 4](#pone.0232635.g004){ref-type="fig"}). Although EGFP-UL42Ct expressed a lower level of its UL42 product than the other constructs in both immunofluorescence and immunoblotting assays, c-Jun was not re-localized to the nuclei in the EGFP-UL42Ct expressing cells, suggesting that the C-terminus of UL42 was not responsible for the activation of c-Jun. It is unlikely that the expression levels of EGFP-UL42 variants affected the nuclear localization and activation of c-Jun, because nuclear accumulation of c-Jun was observed in all cells expressing HA-UL42WT, -UL42PA or -UL42ΔN but not those expressing HA-UL42ΔI, while the expression levels of HA-tagged proteins in individual cells varied significantly. The N-terminal region is thought to contain a regulatory domain for the control of JNK signaling, as the deletion of the N-terminal region enhanced AP-1 activity more than that of UL42WT. Interestingly, the expression of the UL42ΔI mutant did not increase c-Jun nuclear import but induced phosphorylation of c-Jun to the same degree as UL42WT, which is consistent with a previous report that the nuclear import of c-Jun is independent of its phosphorylation \[[@pone.0232635.ref018]\]. Further investigation will be needed to elucidate the precise functional domains of UL42.

In contrast to outcomes in transient transfection assays which performed in HEK293T cells, the lack of UL42 did not affect the phosphorylation status of c-Jun in HCMV-infected fibroblasts ([S3 Fig](#pone.0232635.s005){ref-type="supplementary-material"}). As we did not examine the effects of UL42 constructs in fibroblasts due to a low transfection efficiency, one potential explanation of the discrepancy would be a cell-type specific function of UL42. However, it is more plausible that the presence of multiple mechanisms of the c-Jun phosphorylation in HCMV-infected cells results in the discrepancy. Indeed, the activation of c-Jun/JNK signaling occurs immediately after HCMV infection and a JNK inhibitor, SP600125, inhibits HCMV replication by the suppression of immediate-early gene expression \[[@pone.0232635.ref019]\]. HCMV encodes many c-Jun/JNK signal-modulating proteins, including IE1 and UL38 \[[@pone.0232635.ref006], [@pone.0232635.ref020]\]. IE1, a transactivator encoded by HCMV, promotes phosphorylation of c-Jun through a cellular protein kinase \[[@pone.0232635.ref006], [@pone.0232635.ref021]\]. On the other hand, another HCMV-encoded protein, UL38, which is classified as an early gene product \[[@pone.0232635.ref022]\], reduces JNK phosphorylation to suppress ER stress-induced cell death \[[@pone.0232635.ref020]\]. Previous studies demonstrated that UL42 was classified as a dispensable gene \[[@pone.0232635.ref008], [@pone.0232635.ref023]\], which is consistent with the notion that HCMV has several c-Jun modifying genes. As UL42 is known to be expressed at least 1 day post-infection in HCMV-infected fibroblasts \[[@pone.0232635.ref008]\], we hypothesize that UL42 would contribute to regulate c-Jun/JNK signaling in some manner during the early phase of infection with some HCMV encoded protein(s).

In conclusion, UL42 activated c-Jun/JNK signaling in an Itch-independent manner. The results presented herein indicate that the a.a. 52--86 regions of UL42 is responsible for c-Jun nuclear translocation. This region is important for induction of AP-1 signaling and JNK activation. In the future, it would be interesting to see the Nedd4 family-independent inhibitory effect of UL42 on cyclic GMP-AMP synthase \[[@pone.0232635.ref014]\]. Further research is still required, however, to elucidate the precise mechanisms of the UL42-mediated activation of c-Jun/JNK signaling.
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###### Luciferase assay results of UL42 derivatives.

The luciferase assay results of three independent experiments are shown. A plasmid expressing the indicated UL42 mutant tagged with HA (A) or with EGFP (B), the luciferase reporter plasmid pAP1(PMA)-TA-Luc, and the control plasmid pRL-TK were transfected into HEK293T cells. Ratios of firefly luciferase activities to Renilla luciferase activities obtained in triplicated wells are shown as the means ± SEMs. (A) pCAGGS (Vec), pCAGGS-HAUL42WT (WT), -HAUL42PA (PA), -HAUL42ΔN (ΔN), and -HAUL42ΔI (ΔI). (B) pEGFP-C1 (Vec), -UL42WT (WT), -UL42AY (AY), and -UL42Ct (Ct).

(PPTX)

###### 

Click here for additional data file.

###### Intracellular localization of UL42 derivatives.

HA-tagged UL42 proteins (A) and EGFP-tagged UL42 proteins (B) were expressed in HEK293T cells and analyzed with immunofluorescence assay. A. The cells expressing HA-tagged UL42 derivatives were stained with anti-HA (red) and anti-c-Jun (green) antibodies. The nuclei were stained with DAPI (blue). B. The cells expressing EGFP-tagged UL42 derivatives were reacted with anti c-Jun antibody and then with Alexa Flora 647-conjugated secondary antibody (red). EGFP fluorescence and nuclei staining with DAPI are shown in green and blue, respectively. Bar = 10μm.

(PPTX)

###### 

Click here for additional data file.

###### The phosphorylation status of c-Jun in fibroblasts infected with HCMV wild-type or UL42 mutants.

Fibroblasts, hTERT-BJ1 cell- were mock infected (m) or infected with the following HCMV strains at a multiplicity of infection (MOI) of 5, harvested at 3 day post-infection, and their lysates were analyzed by immunoblotting with the indicated antibodies. WT: HCMV encoding wild-type UL42, R: HCMV encoding rescued UL42, PA: HCMV encoding UL42PA, Δ: HCMV lacking UL42.

(PPTX)

###### 

Click here for additional data file.
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\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: No

Reviewer \#3: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: No

Reviewer \#2: Yes

Reviewer \#3: No

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: No

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: This manuscript by Koshizuka reported that HCMV protein UL42 activated c-Jun/JNK signaling in an Itch-independent manner. Data showed that different structure domains of UL42 may have different functions, as the internal region of UL42 is important for AP-1 transcriptional activation and the c-terminal region of UL42 is necessary for protein stability. It is an incremental yet worthwhile advance in our understanding. However, most experiments were performed in 293T cells by overexpressing UL42 in isolation. It is important to test whether UL42 is able to activate JNK during CMV infection. My specific comments are as follows:

1\. Figure 1,

1\) The reporter plasmid with pAP1 needs a detailed description

2\) Also, the PPXY to PPXA alternation needs be clarified.

3\) Why UL42Ct start from 99aa ratherthan 87aa in the EGFP-UL42Ct mutant?

2\. Figure 2A,

1\) The way of tagging HA in mutants needs more detailed description.

2\) Why the signal intensity of c-Jun is different between vector, △Ct and WT? As is shown in Figure 3 its expression level is similar among the groups. A ratio between nuclear and cytoplasm c-Jun signal may be more convincing, and a statistic analysis is necessary.

3\. Figure 2B, it is necessary to add a positive group "EGFP-ul42wt" to rule out the possibility that EGFP has influence on intracellular localization of c-Jun.

4\. Line 100-103. The conclusion"These results indicate that the C-terminal region of UL42, but not the PY motif, is involved in the activation of AP-1-dependent transcription" may not be accurate, as shown in figure 3, C-terminal domain of UL42 is important for protein stability, so the low luciferase activity may be because of low protein expression level.

5\. Line113-114. The conclusion about C-terminal domain of UL42 may also not be accurate, because the protein expression level of UL42 is extremely low.

6\. line 93 ";" should be ":"

7\. line105 "UL42wt, we" should be "UL42wt. We"

Reviewer \#2: The manuscript by Koshizuka and Inoue shows a novel role for the human cytomegalovirus (HCMV) protein UL42, activating AP-1 via c-Jun and JNK phosphorylation. The authors have previously reported that this viral protein interacts with the ubiquitin E3 ligase Itch, degrading it. They now show, using UL42 mutants, that the functional domain employed by this viral protein to regulate c-Jun activation does not map to the two PPXY motifs responsible of the interaction with Itch, but instead it involves a region containing the C-terminal TMD. Overall, the study reports an interesting observation and suggests a potential contribution of UL42 to viral replication via activation c-Jun/JNK.

However, a mayor problem of the study is the minimal amount of data presented, which in addition do not provide information on the mechanism by which UL42 activates c-Jun and JNK. Another mayor issue lies on the fact that all the observations described in the study are based on the UL42 protein ectopically expressed, and there are not indications that these UL42-mediated processes occur in the context of the HCMV infection. Although HCMV encodes additional proteins that activate the JNK pathway, it would seem important to determine the effect of a HCMV defective in UL42, or more specifically of HCMVs with mutant versions of UL42, in the activation of c-Jun/JNK. In particular, since the authors have previously generated and reported on a HCMV defective on UL42. Finally, the authors do not convincingly determine the region involved in c-Jun/JNK activation, as some conclusions are drawn from mutants with vast deletions, and in the case of UL42�Ct, from a protein with stability problems. Therefore, the introduction of more subtle mutations in UL42 are recommended.

Other concerns:

\- Figure 2B does not include clear pictures that support the conclusions drawn by the authors in the manuscript. It is intriguing why the UL42Ct has been generated as a GFP fusion protein and not as an HA-tagged-protein in the same way as WT UL42 and the rest of UL42 mutants. UL42Ct should be cloned in the HA-based vector and analyzed in this background so results are clearer and they could be directly compared with those obtained with the rest of constructs.

\- The authors should have included the UL42Ct protein in the assays shown in Fig 1 and 3.

\- Conclusions have been drawn based on the UL42�Ct mutant. However, Fig 3 shows that the corresponding protein is not expressed in transfected cells, and the authors indicate that this might be due to the instability of the protein. It is hard to know what to make of it. The observation probably questions the results obtained with this mutant. In addition, if this is the case, why then the authors detect the expression of UL42�Ct by immunofluorescence in Fig. 2A?

\- In order to base conclusions from Fig 2A, images of some of the most relevant immunofluorescence pictures at a higher magnification should have been added.

Minor concerns:

\- The Material and Methods miss information. For example, it does not contain immunoblot or fluorescence microscopy sections that could provide details on the conditions used in these procedures, such as lysis buffer, percentage of SDS-PAGE, permeabilizing conditions, type of microscopy (is it confocal?), or magnification used in the study.

\- The authors have previously reported that UL42 degrades Itch via the two PPXY motifs. However, and although they do not present a quantification of the normalized Itch band, this does not seem the be the case in the western blot shown in Figure 3. They should comment on this.

\- Why in the western blot shown in Fig 3 UL42�N migrates as two bands?

\- The information of the function recently attributed to UL42 (Fu et al. PLoS Pathogens 2019, 15(5): e1007691) should be mentioned in the Introduction too to contextualize the viral protein.

Reviewer \#3: Is the manuscript technically sound, and do the data support the conclusions?

Koshizuka et. al, present evidence herein that the human cytomegalovirus protein UL42 activates c-Jun via JNK in HEK 293T cells. Although the work is technically sound in most places, revisions must be made before the conclusions drawn by the authors are fully supported by the data. One area of concern is Figure 1B, where it is stated that "ratios... obtained in triplicated wells are shown as the mean ±SEM" suggesting that data is from a single experimental repeat. Can this result be reproduced and could the authors show these results as the mean ±SEM from across multiple experimental replicates?

In Figure 2, the authors show that their EGFP-UL42Ct construct does not induce nuclear localization of c-Jun. This is a very interesting and important result. Could the authors therefore also show that this construct does not activate Jun/JNK/AP-1 either by luciferase assay as in figure 1, and/or by immunoblot as in figure 3? This is not vital for the integrity of the manuscript but would greatly enhance the claims being made.

In Figure 3, the authors were unable to detect UL42∆Ct by immunoblot and conclude that UL42∆Ct is too unstable to be detected. This raises problems with their results in Figure 1, as they do not demonstrate that UL42∆Ct was expressed by the cells in this assay. If UL42∆Ct was not being expressed, then the authors cannot conclude that the C terminal TMD is required for UL42-mediated activation of AP-1\...

\...However, in Figure 2A the authors can detect UL42∆Ct by immunofluorescence assay. Figure 2A therefore suggests that UL42∆Ct is expressed just as well as other UL42 mutants. This indicates that there is potentially a problem with the immunoblotting protocol that is used to solubilize and detect UL42 in Figure 3. Since UL42∆Ct is no longer a membrane protein, it could be that a different immunoblotting approach is required to detect it. It is difficult to suggest what other problems may be causing this as the authors have not included a detailed explanation of their immunoblotting protocol in the methods section.

Figure 2 provides strong evidence to support the conclusions drawn by the authors. I believe that the improvements to the data in Figures 1 and 3 that I have stated so far would strengthen the rigor of this manuscript sufficiently to justify the author's conclusions.

Has the statistical analysis been performed appropriately and rigorously?

Statistical analysis, ideally using one-way analysis of variance (ANOVA), needs to be performed for luciferase data in Figure 1B in order to calculate the statistical significance of the results presented. This analysis should be performed on data from three experimental repeats.

Is the manuscript presented in an intelligible fashion and written in standard English?

For a reader without expertise in this field, areas of the manuscript require further details to be intelligible. For example:

• The abbreviations (PA) and (∆N) are not defined in the text.

• A control vector is used, but it is labeled as "V" in Figure 1, "Vector" in Figure 2 and "Vec" in Figure 3. The authors should state if these are the same vector, and what this vector is (I assumed that it is the empty UL42 expression vector, pCAGGS).

• Is anything already known about the internal region or C terminal TMD? If so, this should be detailed in the introduction (or stated that nothing is known).

• When the authors discuss the proximal regions of the C-terminal TMD, is this the same region as the internal region, or are they different? The authors could label Figure 1A to help clarify which regions of UL42 they are discussing.

• The figure legends for figures 1 and 2 need to include definitions for the UL42 mutants, as in figure 3.

There is no mention in the methods section of how immunoblots were performed, a detail which is important for understanding the lack of expression of the ∆Ct mutant in Figure 3. Other details that should be included in the methods section:

• Antibody concentrations for immunofluorescence and immunoblotting

• Antibody incubation conditions

• Enzymes and ligases used for cloning UL42 into the pCAGGs vector would be useful

• The amount of each plasmid that was transfected for each assay

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: Yes: Dr Benjamin Anthony Krishna

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

###### 

Submitted filename: Review Report Koshizuka.pdf

###### 

Click here for additional data file.

10.1371/journal.pone.0232635.r002

Author response to Decision Letter 0

19 Mar 2020

Responses to Reviewer's comments

MS\#:PONE-D-20-02197

We thank you for your review on our manuscript. To accommodate your comments, we added a couple of experiments and modified the text, figures and supplementary materials as described below. Line numbers indicated by the reviewers are based on the original manuscript and those by us are based on the revised manuscript with tracked changes (file: PONE-D-20-02197 Revised Manuscript with Track Changes).

Reviewer \#1

General comment: It is important to test whether UL42 is able to activate JNK during CMV infection.

Response:　To accommodate the comment, we conducted an additional experiment using recombinant HCMV strains with mutated versions of UL42 and found that HCMV infection induced c-Jun phosphorylation although the deletion of UL42 did not affect the c-Jun phosphorylation status in HCMV infected cells. These results could be explained by the presence of multiple mechanisms of the c-Jun phosphorylation in HCMV-infected cells. To describe our observation and discussion on this observation, we added immunoblot images as Figure S2 as well as sentences describing construction of recombinant HCMV strains (lines 143- 156), the results (lines 228-230) and discussion (lines 259- 261).

Comment 1 (Figure 1): The reporter plasmid with pAP1 needs a detailed description. Also, the PPXY to PPXA alternation needs be clarified. Why UL42Ct start from 99aa rather than 87aa in the EGFP-UL42Ct mutant?

Response: We used a commercial reporter plasmid, pAP1(PMA)-TA-Luc, which contains multiple copies of the AP1 element and a minimal promoter, located upstream of the firefly luciferase gene. Descriptions of these details were added into the text (lines 98- 102).

Construction of the UL42PA mutant was described in our previous study (Koshizuka et al., 2016 J. Gen. Virol.).　 Briefly, tyrosine (Y) codons in the two PPXY (PY) motifs were replaced with alanine (A) codons by site-directed mutagenesis, resulting in the two PPXA (PA) motifs.　 We modified the text for clarification (lines 175-179).

Thanks for pointing out the error of the UL42Ct start site. EGPF-UL42Ct should contain amino acid residues from 87 to 124. Accordingly, Figure 1A was corrected.

Comment 2 (Figure 2A): The way of tagging HA in mutants needs more detailed description. Why the signal intensity of c-Jun is different between vector, △Ct and WT? As is shown in Figure 3 its expression level is similar among the groups. A ratio between nuclear and cytoplasm c-Jun signal may be more convincing, and a statistic analysis is necessary.

Response: The details of construction of HA-tagged UL42 plasmids were added to the Materials and Methods section (lines 77-83).

As the reviewer noticed, although the amounts of c-Jun in the cells were at a similar level in immunoblotting, the signal intensities of c-Jun were different in spite of the use of the same anti-c-Jun antibody in both assays. We assume that the used antibody reacted better for nuclear c-Jun.

To accommodate the comment, the percentages of cells containing nuclear c-Jun among the cells expressing UL42WT or mutated versions were obtained for statistical analyses. Descriptions for the procedures and for the statistical results were added to the Materials and Methods section (lines 158-168) and to the Results section (lines 198-201 and 210-212), respectively. The statistically significances are also shown in the revised Figures 1B, 1C, 2B and 3B.

Comment 3: Figure 2B, it is necessary to add a positive group "EGFP-UL42wt" to rule out the possibility that EGFP has influence on intracellular localization of c-Jun.

Response: As suggested by the reviewer, we conducted an experiment that included EGFP-UL42WT and -UL42AY as controls (Figures 3 and 4 in the revised manuscript). Both EGFP-UL42WT and -UL42AY induced AP1 signaling and c-Jun nuclear accumulation and phosphorylation, which is consistent with the results using HA-tagged UL42 derivatives. To describe those results, the text was modified (lines 84-89, 181-185, 202-213, and 226-227).

Comment 4: Line 100-103. The conclusion "These results indicate that the C-terminal region of UL42, but not the PY motif, is involved in the activation of AP-1-dependent transcription" may not be accurate, as shown in figure 3, C-terminal domain of UL42 is important for protein stability, so the low luciferase activity may be because of low protein expression level. Line113-114. The conclusion about C-terminal domain of UL42 may also not be accurate, because the protein expression level of UL42 is extremely low.

Response: In an additional experiment using EGFP-fusion proteins (revised Fig. 1C and Fig. 3), we found that the C-terminal transmembrane domain of UL42 alone did not accumulate c-Jun in the nuclei nor activated c-Jun. As criticized by the reviewer, the amounts of HA-tagged UL42ΔCt protein fluctuated from one experiment to another due to the stability issue. Taking account of the additional results and the stability issue, we removed the results obtained by expression of HA-tagged UL42ΔCt and modified our conclusion.

Minor comment1: line 93 ";" should be ":"

Minor comment 2: line105 "UL42wt, we" should be "UL42wt. We"

Response: As suggested, we corrected those errors (lines 114-118, and 181).

Reviewer \#2

General comment 1:

However, a major problem of the study is the minimal amount of data presented, which in addition do not provide information on the mechanism by which UL42 activates c-Jun and JNK. Another major issue lies on the fact that all the observations described in the study are based on the UL42 protein ectopically expressed, and there are not indications that these UL42-mediated processes occur in the context of the HCMV infection. Although HCMV encodes additional proteins that activate the JNK pathway, it would seem important to determine the effect of a HCMV defective in UL42, or more specifically of HCMVs with mutant versions of UL42, in the activation of c-Jun/JNK. In particular, since the authors have previously generated and reported on a HCMV defective on UL42. Finally, the authors do not convincingly determine the region involved in c-Jun/JNK activation, as some conclusions are drawn from mutants with vast deletions, and in the case of UL42ΔCt, from a protein with stability problems. Therefore, the introduction of more subtle mutations in UL42 are recommended.

Response: As described in the response to Reviewer \#1's General comment, we conducted an additional experiment using recombinant HCMV strains and found that the lack of UL42 did not affect the c-Jun phosphorylation status in HCMV-infected cells. These results could be explained by the presence of multiple mechanisms of the c-Jun phosphorylation in HCMV-infected cells. We added the immunoblot images as Figure S2 and modified the text (lines 143-156, and 259-261).

In addition, we conducted addition experiments using plasmids expressing EGFP-tagged UL42 derivatives and found that both EGFP-UL42WT and -UL42AY activated AP-1 signaling. These observations were consistent with the results using the plasmids expressing HA-tagged proteins. At the same time, AP-1 activation, nuclear accumulation of c-Jun and c-Jun phosphorylation were significantly reduced in the cells expressing EGFP-UL42Ct. Therefore, it is likely that the C-terminal TMD was not involved in AP-1 signaling. We modified the text (lines 84-89, 181-185, 202-213, and 226-227) and revised Fig. 1C and Fig. 3. As criticized by the reviewer, the amounts of HA-tagged UL42ΔCt protein fluctuated from one experiment to another due to the stability issue. Taking account of the additional results and the stability issue, we removed the results obtained by expression of HA-tagged UL42ΔCt, and modified our conclusion.

As we agree with the need of experiments using more subtle mutations, we would like to address such a fine mapping in the next step. We added a description regarding this issue as one of limitations of this study (lines 257-258).

Comment 1: Figure 2B does not include clear pictures that support the conclusions drawn by the authors in the manuscript. It is intriguing why the UL42Ct has been generated as a GFP fusion protein and not as an HA-tagged-protein in the same way as WT UL42 and the rest of UL42 mutants. UL42Ct should be cloned in the HA-based vector and analyzed in this background so results are clearer and they could be directly compared with those obtained with the rest of constructs.

Response: To make UL42Ct data comparable with HA-tagged UL42 derivatives, we added a plasmid expressing EGFP-UL42WT as a positive control and a plasmid expressing UL42AY as a PPxY mutant in the revised Fig. 3. In addition, to show clear subcellular localization, the data of immunofluorescence assay at a higher magnification were added as Figure S1. Accordingly, the text was modified (lines 84-89, 181-185, 202-213, and 226-227)

Comment 2: The authors should have included the UL42Ct protein in the assays shown in Fig 1 and 3.

Comment 3: Conclusions have been drawn based on the UL42ΔCt mutant. However, Fig 3 shows that the corresponding protein is not expressed in transfected cells, and the authors indicate that this might be due to the instability of the protein. It is hard to know what to make of it. The observation probably questions the results obtained with this mutant. In addition, if this is the case, why then the authors detect the expression of UL42ΔCt by immunofluorescence in Fig. 2A?

Response: As described for Comment 1, we added EGFP-UL42WT and UL42AY to compare with EGFP-UL42Ct and the C-terminal TMD of UL42 was not involved in AP-1 activation. Taking account of the new results, we modified our conclusion.

Comment 4: In order to base conclusions from Fig 2A, images of some of the most relevant immunofluorescence pictures at a higher magnification should have been added.

Response: As suggested, we added the immunofluorescence assay images at a higher magnification as Figure S1.

Minor concerns:

Comment 5: The Material and Methods miss information. For example, it does not contain immunoblot or fluorescence microscopy sections that could provide details on the conditions used in these procedures, such as lysis buffer, percentage of SDS-PAGE, permeabilizing conditions, type of microscopy (is it confocal?), or magnification used in the study.

Response: As suggested by the reviewer, we intensively modified the Materials and Methods section (lines 67-168).

Comment 6: The authors have previously reported that UL42 degrades Itch via the two PPXY motifs. However, and although they do not present a quantification of the normalized Itch band, this does not seem to be the case in the western blot shown in Figure 3. They should comment on this.

Response: In order to show more clear results, the immunoblot image of Itch in Figure 4A was revised. As shown in Figure 4A, Itch was decreased in UL42WT and ΔI expressing cells but not in UL42PA or ΔN expressing cells.

Comment 6: Why in the western blot shown in Fig 3 UL42ΔN migrates as two bands?

Response: Based on the molecular weights of the two bands, we assume that they are products of proteolytic cleavage (lines 218-219).

Comment 7: The information of the function recently attributed to UL42 (Fu et al. PLoS Pathogens 2019, 15(5): e1007691) should be mentioned in the Introduction too to contextualize the viral protein.

Response: As suggested by the reviewer, we described the study in the Introduction section (lines 56 -- 59).

Reviewer \#3

General comment: Although the work is technically sound in most places, revisions must be made before the conclusions drawn by the authors are fully supported by the data. One area of concern is Figure 1B, where it is stated that "ratios... obtained in triplicated wells are shown as the mean ±SEM" suggesting that data is from a single experimental repeat. Can this result be reproduced and could the authors show these results as the mean ±SEM from across multiple experimental replicates?

Response: Our luciferase assay results are based on three independent experiments and each set of experimental results was analyzed with the one-way ANOVA test followed by the Tukey's comparison test using GraphPad PRISM software. The data obtained in triplicated wells of one of three independent experiments are presented as Figure 1B and C. The text were revised for clarification (lines 159-168 and 372-380).

Comment 1: In Figure 2, the authors show that their EGFP-UL42Ct construct does not induce nuclear localization of c-Jun. This is a very interesting and important result. Could the authors therefore also show that this construct does not activate Jun/JNK/AP-1 either by luciferase assay as in figure 1, and/or by immunoblot as in figure 3? This is not vital for the integrity of the manuscript but would greatly enhance the claims being made.

Response: To accommodate this comment, EGFP-UL42WT and UL42AY were added in this manuscript as controls for EGFP-UL42Ct. AP-1 signal was activated and c-Jun was accumulated to nucleus by expression of EGFP-UL42WT and -UL42AY but not by EGFP-UL42Ct. To describe these results, the text was modified (lines 84-89, 181-185, 202-213, and 226-227) and revised Fig. 1C and Fig. 3.

Comment 2: In Figure 3, the authors were unable to detect UL42∆Ct by immunoblot and conclude that UL42∆Ct is too unstable to be detected. This raises problems with their results in Figure 1, as they do not demonstrate that UL42∆Ct was expressed by the cells in this assay. If UL42∆Ct was not being expressed, then the authors cannot conclude that the C terminal TMD is required for UL42-mediated activation of AP-1.

Comment 3: However, in Figure 2A the authors can detect UL42∆Ct by immunofluorescence assay. Figure 2A therefore suggests that UL42∆Ct is expressed just as well as other UL42 mutants. This indicates that there is potentially a problem with the immunoblotting protocol that is used to solubilize and detect UL42 in Figure 3. Since UL42∆Ct is no longer a membrane protein, it could be that a different immunoblotting approach is required to detect it. It is difficult to suggest what other problems may be causing this as the authors have not included a detailed explanation of their immunoblotting protocol in the methods section.

Response: As described for the comments of Reviewers \#1 and \#2, we conducted addition experiments using plasmids expressing EGFP-fusion proteins and found that both EGFP-UL42WT and -UL42AY activated AP-1 signaling. These observations were consistent with the results using the plasmids expressing HA-tagged proteins. As in the same experiments, AP-1 activation and c-Jun phosphorylation were significantly reduced in the cells expressing EGFP-UL42Ct, it is likely that the C-terminal TMD was not involved in AP-1 signaling. We modified the text (lines 84-89, 181-185, 202-213, and 226-227) and revised Fig. 1C and Fig. 3. As criticized by the reviewer, the amounts of HA-tagged UL42ΔCt protein fluctuated from one experiment to another due to the stability issue. Taking account of the additional results and the stability issue, we removed the results obtained by expression of HA-tagged UL42ΔCt and modified our conclusion.

Comment 4: Figure 2 provides strong evidence to support the conclusions drawn by the authors. I believe that the improvements to the data in Figures 1 and 3 that I have stated so far would strengthen the rigor of this manuscript sufficiently to justify the author's conclusions.

Response: To accommodate the comment, we added the statistical analysis in Figures 1 and 2. In addition, we added EGFP-UL42WT and -UL42AY to compare EGFP-UL42Ct (revised Fig. 3).

Comment 5: Has the statistical analysis been performed appropriately and rigorously?

Comment 6: Statistical analysis, ideally using one-way analysis of variance (ANOVA), needs to be performed for luciferase data in Figure 1B in order to calculate the statistical significance of the results presented. This analysis should be performed on data from three experimental repeats.

Response: As suggested, we conducted statistical analyses using GlaphPad PRISM software. All statistical analysis was performed on data from three independent experiments and we confirmed that these data were significant statistically. The text was revised (lines 158-168, 374-378, 388-392, and 398-401).

Comment 7: Is the manuscript presented in an intelligible fashion and written in standard English?

Response: Our manuscript was edited commercially by an English-native scientific editor.

Comment 8-1: The abbreviations (PA) and (∆N) are not defined in the text.

Response: Sentences describing the definitions of PA and ∆N were added to the text (lines 79-83, and 179-181).

Comment 8-2: A control vector is used, but it is labeled as "V" in Figure 1, "Vector" in Figure 2 and "Vec" in Figure 3. The authors should state if these are the same vector, and what this vector is (I assumed that it is the empty UL42 expression vector, pCAGGS).

Response: We modified the legends for these figures.

Comment 8-3: Is anything already known about the internal region or C terminal TMD? If so, this should be detailed in the introduction (or stated that nothing is known).

Response: As there are no additional information about the domain mapping of UL42, the text was revised for clarification (lines 49-52).

Comment 8-4: When the authors discuss the proximal regions of the C-terminal TMD, is this the same region as the internal region, or are they different? The authors could label Figure 1A to help clarify which regions of UL42 they are discussing.

Response: For clarification, the sentence was revised (line 212-213, 246-249, and 275-276).

Comment 8-5: The figure legends for figures 1 and 2 need to include definitions for the UL42 mutants, as in figure 3.

Response: The legends were revised (lines 378-380, 383-387, and 398-400).

Comment 9: There is no mention in the methods section of how immunoblots were performed, a detail which is important for understanding the lack of expression of the ∆Ct mutant in Figure 3. Other details that should be included in the methods section:

• Antibody concentrations for immunofluorescence and immunoblotting

• Antibody incubation conditions

• Enzymes and ligases used for cloning UL42 into the pCAGGS vector would be useful

• The amount of each plasmid that was transfected for each assay

Response: The Materials and Methods section were intensively revised to include these information. (lines 76-95, 97-104, 106-118, and 120-141)

Others

1\. To increase readability, the text was edited without losing the original contents.

2\. Primers names were simplified.

###### 

Submitted filename: PONE-D-20-02197 Response to Reviewers.docx

###### 

Click here for additional data file.

10.1371/journal.pone.0232635.r003

Decision Letter 1

Nevels

Michael

Academic Editor

© 2020 Michael Nevels

2020

Michael Nevels

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

2 Apr 2020

PONE-D-20-02197R1

Activation of c-Jun by human cytomegalovirus UL42 through JNK activation.

PLOS ONE

Dear Dr. Koshizuka,

Thank you for submitting your revised manuscript to PLOS ONE. Please address the remaining minor issues two of the referees have raised.

We would appreciate receiving your revised manuscript by May 17 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Michael Nevels

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: All comments have been addressed

Reviewer \#3: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: This manuscript is a revised version of one I previously reviewed. It is much better that the authors have addressed most of my comments. However, there are still some problems need to be corrected

Minor issues: line247-248 "c-Jun" should be "C-Jun"

Line246-247 needs rephrasing.

Line184-185, this sentence is confusing, according to the results, "except for" should be "rather than"

Comment 1: Figure 1. It is good to use HA and GFP to rule out the effects of tag protein on results. But the experiments control from this two different tag groups should keep consistent.

Tagged-UL42WT, -UL42N, -UL42I, -UL42PY, -UL42AY, and -CT should be included in both two groups.

Comment 2: Line226-227. "c-Jun and JNK were phosphorylated by the expression of EGFP-UL42WT and -UL42AY but not by EGFP-UL42Ct." But as Figure 4B shows, the phosphorylation level of c-Jun by EGFP-UL42Ct is almost the same as EGFP-UL42WT and UL42AY and the phosphorylation level of JNK by EGFP-UL42Ct is nearly to EGFP-UL42AY.

More experiment controls need to be set to explain this problem or the conclusion need to be amended.

Comment 3 : Line 275-276. As comment 2 mentioned, taken all results into consideration, aa52-86 region of UL42 is just responsible for Jun translocation to nucleus.

Reviewer \#2: The authors have addressed most of the concerns previously raised. I beleive that the manuscript is now suitable for publication.

The legend to Fig S2 needs to be revised. It is not correct to state \"Fibroblasts infected with mock (m) \...\"

Reviewer \#3: I would like to thank Koshizuka and Inoue for the changes they have made to their manuscript, which shows that the HCMV gene UL42 activates Jun in transfected HEK293T cells, and that the internal region is important for this activity. As suggested, they have better defined their materials and constructs, which helps the reader to understand the manuscript. Could the authors make the following changes to their figures to improve reader understanding:

-Figure 1B shows the results from one of three experiments, including statistical analysis. Could the authors include the data for the other two experiments, either as mean averages in Figure 1B, or at least in the supplemental section as two separate figures?

-In Figure 2B, could the authors include the empty vector control in their quantification of Jun positive nuclei? Could the authors also label the y axis to describe what this graph shows? Similarly for Figure 3B, the y axis needs a label.

-Figure S1A requires an empty vector control.

Some changes also need to be made to the text:

-The sentence in results section lines 181-185 does not make sense. I think that removing the word \"and\" so that this reads: \"\...the PY motifs is essential for the activation of AP-1 dependent transcription\" is what the authors want to say.

\- In figures 3A and 4B, EGFP-Ct is detectable by immunofluorescence but not by western blot. The authors suggest that the difference in their observation is due to variable protein stability. Having examined figures 3A and S1B, it does appear as if the EGFP-UL42Ct construct has weaker fluorescence than the other constructs. Would the authors agree with this, as it would then make their results consistent? If so, could the authors mention this weaker fluorescence in the discussion.

\- The final paragraph of the results section describes the infection assay performed by the authors. Could the authors include details such as cell type infected, multiplicity of infection and the duration of infection? This information is vital to analyzing this data and should be mentioned in the results as well as the figure legend. Perhaps, for example, if the authors have infected these cells at a higher MOI (higher than 1) this could lead to significant activation of Jun simply due to the large amount of virus present. Using a lower MOI may therefore reveal differences between WT and UL42 deletion viruses for Jun activation. Without this information, it is hard to determine the validity of this result.

\- It is not surprising that there was no difference between WT and the UL42 deletion mutant for Jun activation, given that other HCMV genes also activate Jun, as stated by the authors. As I understand it, Dunn et al showed in 2003 that UL42 is dispensable for infection in fibroblasts. This should be mentioned by the authors as it supports the notion that UL42\'s function is redundant during infection.

\- As the transfection assays were performed in HEK293T cells, and the infections performed in fibroblasts, could activation of Jun by UL42 be cell-type specific? The authors could either perform transient transfection assays in fibroblasts to resolve this difference, or simply moderate their discussion section to specify that this observation is in transfection assays of HEK293T cells and not fibroblasts.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: Yes: Benjamin Krishna

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 1

17 Apr 2020

Responses to Reviewer's comments

MS\#:PONE-D-20-02197R1

We thank you for your review on the revised version of our manuscript. To accommodate your comments, we modified the text and supplementary materials as described below. Line numbers indicated by the reviewers are based on the revised manuscript and those by us are based on the re-revised manuscript with tracked changes (file: PONE-D-20-02197R1 Revised Manuscript with Track Changes).

Reviewer \#1

Comment 1 (Figure 1): It is good to use HA and GFP to rule out the effects of tag protein on results. But the experiments control from this two different tag groups should keep consistent. Tagged-UL42WT, -UL42N, -UL42I, -UL42PY, -UL42AY, and -CT should be included in both two groups.

Response: We used EGFP-UL42Ct to confirm the requirement of the UL42 C-terminus region for activation of c-Jun/JNK signaling. On the other hand, the EGFP-UL42AY mutant was used for a separate issue, that is, confirmation of no involvement of the Nedd4 family E3 ligases in the c-Jun/JNK signaling. The text was revised to clarify the respective purposes of these constructs (lines 181-185).

Comment 2: Line226-227. "c-Jun and JNK were phosphorylated by the expression of EGFP-UL42WT and -UL42AY but not by EGFP-UL42Ct." But as Figure 4B shows, the phosphorylation level of c-Jun by EGFP-UL42Ct is almost the same as EGFP-UL42WT and UL42AY and the ph9osphorylation level of JNK by EGFP-UL42Ct is nearly to EGFP-UL42AY. More experiment controls need to be set to explain this problem or the conclusion need to be amended.

Response: Although the phosphorylation level of c-Jun seems weak in EGFP-UL42WT and -AY expressing cells, the phosphorylation of JNK was significantly increased in EGFP-UP42WT or -AY expressing cells but not in EGFP-UL42Ct expressing cells (Fig.4B). In addition, the results of luciferase assay (Fig.1C) and nuclear translocation of c-Jun (Fig.3) supported the notion that the phosphorylation of c-Jun and activation of AP-1 signaling occurred by expression of EGFP-UL42WT or -AY but not by expression of EGFP-UL42Ct. To accommodate the reviewer's comment, we added some sentences discussing the issue (lines 246-253)

Comment 3 : Line 275-276. As comment 2 mentioned, taken all results into consideration, aa52-86 region of UL42 is just responsible for Jun translocation to nucleus.

Response: We agree. To accommodate the comment, we modified the text (lines 298-299)

Minor comments:

1\. line247-248 "c-Jun" should be "C-Jun"

2\. Line246-247 needs rephrasing.

3\. Line184-185, this sentence is confusing, according to the results, "except for" should be "rather than"

Response: As suggested, these sentences were corrected or rephrased (lines 196, 202, and 230 for \#1, lines 256-259 for \#2, and lines 185-189 for \#3).

Reviewer \#2

Minor comment 1:

The legend to Fig S2 needs to be revised. It is not correct to state \"Fibroblasts infected with mock (m) \...\"

Response: As suggested, the sentence was corrected (lines 465-471).

Reviewer \#3

Comment 1: Figure 1B shows the results from one of three experiments, including statistical analysis. Could the authors include the data for the other two experiments, either as mean averages in Figure 1B, or at least in the supplemental section as two separate figures?

Response: As suggested, we revised the sentences describing that the results of Figure 1B and 1C indicated the means of three independent experiments. In addition, we added a supplementary figure (S1 Figure) showing the three independent sets of results (lines 103-105 and 401-404, and 445-453).

Comment 2: In Figure 2B, could the authors include the empty vector control in their quantification of Jun positive nuclei? Could the authors also label the y axis to describe what this graph shows? Similarly for Figure 3B, the y axis needs a label.

Comment 3: Figure S1A requires an empty vector control.

Response: Figure 2B presented the percentage of nuclear c-Jun positive cells in cells expressing HA-UL42 or its variant. It is technically hard to use the empty vector (pCAGGS) for the quantification, as it does not express detectable HA-tagged protein, which is a situation different from that of the empty vector for EGFP fusion. In the same context, it is impossible to add an image with an empty vector control in Figure S1A, as we have no way to distinguish cells transfected with the empty vector from those not transfected. As suggested, the labels of y axis were added to Figures 2B and 3B.

Minor comment 1: The sentence in results section lines 181-185 does not make sense. I think that removing the word \"and\" so that this reads: \"\...the PY motifs is essential for the activation of AP-1 dependent transcription\" is what the authors want to say.

Response: As suggested, we corrected the sentence (lines 185-189).

Minor comment 2: In figures 3A and 4B, EGFP-Ct is detectable by immunofluorescence but not by western blot. The authors suggest that the difference in their observation is due to variable protein stability. Having examined figures 3A and S1B, it does appear as if the EGFP-UL42Ct construct has weaker fluorescence than the other constructs. Would the authors agree with this, as it would then make their results consistent? If so, could the authors mention this weaker fluorescence in the discussion.

Response: We agreed the reviewer's comment. We pointed out the weaker signals in the Result section and discussed the issue (lines 260-268).

Minor comment 3: The final paragraph of the results section describes the infection assay performed by the authors. Could the authors include details such as cell type infected, multiplicity of infection and the duration of infection? This information is vital to analyzing this data and should be mentioned in the results as well as the figure legend. Perhaps, for example, if the authors have infected these cells at a higher MOI (higher than 1) this could lead to significant activation of Jun simply due to the large amount of virus present. Using a lower MOI may therefore reveal differences between WT and UL42 deletion viruses for Jun activation. Without this information, it is hard to determine the validity of this result.

Response: As requested, we added the details of infection conditions in the legend for Figure S3 of this revised manuscript (lines 465-471).

Minor comment 4: It is not surprising that there was no difference between WT and the UL42 deletion mutant for Jun activation, given that other HCMV genes also activate Jun, as stated by the authors. As I understand it, Dunn et al showed in 2003 that UL42 is dispensable for infection in fibroblasts. This should be mentioned by the authors as it supports the notion that UL42\'s function is redundant during infection.

Response: As suggested, a sentence describing the previous studies with citations, including Dunn et al, was added (lines 290-292).

Minor comment 5: As the transfection assays were performed in HEK293T cells, and the infections performed in fibroblasts, could activation of Jun by UL42 be cell-type specific? The authors could either perform transient transfection assays in fibroblasts to resolve this difference, or simply moderate their discussion section to specify that this observation is in transfection assays of HEK293T cells and not fibroblasts.

Response: It is very important point, but we did not determine the cell type specificity of the activation of AP-1 signaling by UL42. As the fibroblast cells which we used have very low transfection efficiency, it is difficult to analyze the effects quantitatively. As suggested, we clarified that the observation was in HEK293T cells and addressed the issue in Discussion (lines 276-282).

Others:

We rephrased "293T cells" as "HEK293T cells".

###### 

Submitted filename: 1 PONE-D-20-0219R1 Response to Reviewers.docx
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Click here for additional data file.
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2020

Michael Nevels
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, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

20 Apr 2020

Activation of c-Jun by human cytomegalovirus UL42 through JNK activation.

PONE-D-20-02197R2

Dear Dr. Koshizuka,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Michael Nevels

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

10.1371/journal.pone.0232635.r006
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Academic Editor
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This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

24 Apr 2020

PONE-D-20-02197R2

Activation of c-Jun by human cytomegalovirus UL42 through JNK activation.

Dear Dr. Koshizuka:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Michael Nevels

Academic Editor

PLOS ONE
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